New TYK2 Inhibitors for Psoriasis Achieve High Clearance Rates in Randomized Trials
https://www.profitableratecpm.com/f4ffsdxe?key=39b1ebce72f3758345b2155c98e6709c
(MedPage Today) — DENVER — Two drug candidates intended to expand oral treatment options for psoriasis showed similar and consistent performance in separate Phase III clinical trials reported here. The allosteric TYK2 inhibitor zasocitinib was obtained from…
